We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02970318
Previous Study | Return to List | Next Study

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

This study is currently recruiting participants.
Verified May 2017 by Acerta Pharma BV
Sponsor:
ClinicalTrials.gov Identifier:
NCT02970318
First Posted: November 22, 2016
Last Update Posted: May 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Acerta Pharma BV
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2020
  Estimated Primary Completion Date: January 2020 (Final data collection date for primary outcome measure)